Rival BTK degraders face off in CLL patients naive to BTK inhibition.
ApexOnco Front Page
Recent articles
Talvey looks good with Darzalex in the second line, while Pomalyst’s role is less clear.
Lilly buys the dual-payload ADC specialist before it’s dosed a single patient.
The group impresses in ovarian and endometrial cancers.
After setbacks, cema-cel might have a path to approval in lymphoma.
Optimum-02 virtually replicates phase 1, and a filing will follow.
The oncolytic virus vuso-vec is slapped with its second CRL.
After opting in last year, Gilead picks up Kymera's KT-200.
